Skip to content

A randomized controlled study on the clinical efficacy and safety of Tangshenfang dispensing granule compared with traditional decoction for diabetic kidney disease of qi-yin deficiency

A randomized controlled study on the clinical efficacy and safety of Tangshenfang dispensing granule compared with traditional decoction for diabetic kidney disease of qi-yin deficiency

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000149
Enrollment
Unknown
Registered
2025-01-17
Start date
2025-02-01
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic kidney disease

Interventions

TS_QK group:Basic treatment ( Take Dapagliflozin as the basic blood sugar control plan)+TangShenFang granule of all-square mixed extraction
TS_K1 group:Basic treatment ( Take Dapagliflozin as the basic blood sugar control plan)+Tangshenfang dispensing granule
control group:Basic treatment ( Take Dapagliflozin as the basic blood sugar control plan)+placebo
TS_K2 group:Basic treatment ( Take Dapagliflozin as the basic blood sugar control plan)+Tangshenfang dispensing granule 0.7 times dosage

Sponsors

GuangDong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1: Meet the diagnostic criteria of type 2 diabetes and diabetic kidney disease of stage ?? 2: Fasting blood glucose less than 8mmol/L and 2-hour postprandial blood glucose less than 11mmol/L 3: Older than 18 and younger than 75 4: Participate in the study voluntarily and sign the informed consent form

Exclusion criteria

Exclusion criteria: 1: Women who are pregnant preparing for pregnancy or nursing 2: Patients with acute complications of diabetes mellitus 3: Complicated with serious liver and kidney function damage or serious primary diseases of respiratory circulatory digestive urinary and blood systems. 4: People with allergies and previous allergies to the drugs of this study 5: People with proteinuria caused by other reasons 6: Patients participating in clinical trials of other drugs 7: People with mental illness or disobeying the doctor's advice and be failure to cooperate with treatment

Design outcomes

Primary

MeasureTime frame
Urine albumin creatinine ratio;Serum creatinine;Estimated glomerular filtration rate;Blood urea nitrogen;Urine protein creatinine ratio;

Secondary

MeasureTime frame
Triglyceride;2-hour postprandial blood glucose;Total cholesterol;Low-Density Lipoprotein Cholesterol;High density lipoprotein cholesterol;Glycated hemoglobin;Traditional Chinese medicine syndrome score;Fasting blood glucose;

Countries

China

Contacts

Public ContactZhao Ling

GuangDong Provincial Hospital of Chinese Medicine

18818866015@163.com18818866015

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026